lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
1,170 rows where filing_year = 2022 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2769200 | PORT SIDE STRATEGIES, LLC 1bbe5953-16f6-4a89-ae89-7db7150b1009 | 1T | PORT SIDE STRATEGIES, LLC | 401105394 | SIXTEEN THIRTY FUND | 2022 | first_quarter | PHA | Lobbied in support of including drug pricing reforms in the reconciliation bill/Build Back Better Act. Lobbied in support of efforts to lower drug prices through march-in or government use rights. H.R. 6392 - No Tax Breaks for Drug Ads Act -- in support. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2022-03-17T13:17:07-04:00 | ||
| 2769675 | PENN AVENUE PARTNERS 4e1165f7-04c8-4cd0-a7f7-46c1e1407c10 | Q1 | PENN AVENUE PARTNERS | 400918672 | ALKERMES, INC. | 2022 | first_quarter | PHA | Regulatory and legislative issues impacting Alkermes. S.3593 - Telehealth Extension and Evaluation Act. Public Law No: 117-103 Consolidated Appropriations Act, 2022. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-04T10:28:51-04:00 | |
| 2769840 | PENN AVENUE PARTNERS a03688c3-97a8-4091-9f0b-b559300ed3bb | Q1 | PENN AVENUE PARTNERS | 400918672 | UNITEDHEALTH GROUP, INC. | 2022 | first_quarter | PHA | Pharmacy benefit related issues. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office | 90000 | 0 | 0 | 2022-04-04T17:44:01-04:00 | |
| 2769842 | AMERICAN COLLEGE OF CLINICAL PHARMACY 7fe58b10-f35c-499a-83fb-6cd4c6644efa | Q1 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2022 | first_quarter | PHA | Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. | HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2022-04-04T17:45:12-04:00 | |
| 2769864 | THORSEN FRENCH ADVOCACY LLC 31a406a2-5562-4362-9be1-25416c42e10d | 1T | THORSEN FRENCH ADVOCACY LLC | 400599826 | HEALTHCARE DISTRIBUTION ALLIANCE | 2022 | first_quarter | PHA | Issues related to pharmaceutical supply chain resiliency. Issues related to H.R.768/S.__: Block, Report, And Suspend Suspicious Shipments Act of 2021. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 1 | 2022-04-04T21:34:53-04:00 | |
| 2769978 | MUSCULAR DYSTROPHY ASSOCIATION, INC. 9b17da81-b39a-4ef7-8ae6-23a961f4245d | Q1 | MUSCULAR DYSTROPHY ASSOCIATION, INC. | 400348610 | MUSCULAR DYSTROPHY ASSOCIATION, INC. | 2022 | first_quarter | PHA | Advocated for funding and implementation of the ACT for ALS, a law that should accelerate development of treatments for individuals with ALS and other neuromuscular diseases. Advocated for the passage of the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706) Provided feedback and comments to the Senate's PREVENT Act. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2022-04-05T14:19:01-04:00 | |
| 2770207 | CARD & ASSOCIATES, LLC 80b41dd8-767c-4706-9508-5c5ec9e63450 | Q1 | CARD & ASSOCIATES, LLC | 84217 | AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) | 2022 | first_quarter | PHA | Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitoring federal appropriations for FY 2022 Access to telemedicine | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-06T16:01:27-04:00 | |
| 2770247 | STONINGTON GLOBAL d2f1b2a5-f792-4788-873b-2d40559ed0cf | Q1 | STONINGTON GLOBAL | 401105189 | SORRENTO THERAPEUTICS, INC. | 2022 | first_quarter | PHA | Regulatory approvals and funding for pharmaceutical products and devices | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 150000 | 0 | 0 | 2022-04-06T17:40:20-04:00 | |
| 2770259 | ACG ADVOCACY 886045da-fe03-4643-9f73-5469ef126696 | Q1 | ACG ADVOCACY | 2057 | WALGREEN CO. | 2022 | first_quarter | PHA | Drug Pricing Policy Issues. Data privacy and DIR fee reform. Counterfeiting Issues. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-06T18:29:16-04:00 | |
| 2770369 | RAY ANDERSON 7e5ac1c7-47be-4930-a211-009fa4a79133 | Q1 | RAY ANDERSON | 401105487 | 340B HEALTH | 2022 | first_quarter | PHA | Requesting the Secretary of Health and Human Services and HRSA to enforce a statute ordering drug companies to restore 340B discounts to eligible hospitals Requesting Centers for Medicare and Medicaid Services to restore the Medicare hospital Outpatient Prospective Payment System reimbursement rate Requested Representative Spanberger and Representative Danny K. Davis and members of the Congressional Black Caucus participation in a Congressional Special Order Hour session. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA) | 15000 | 0 | 0 | 2022-04-07T14:24:13-04:00 | |
| 2770673 | VICKI J HICKS f2492735-ab4d-4b1b-8055-741327b3530e | Q1 | VICKI J HICKS | 401106146 | A2 STRATEGIES, LLC OBO PHIBRO ANIMAL HEALTH CORPORATION | 2022 | first_quarter | PHA | Animal health issues. | SENATE | 10000 | 0 | 0 | 2022-04-08T11:28:54-04:00 | |
| 2770684 | MCDERMOTT+ LLC 563b81d1-a87e-42a0-bf44-544e2ace32cd | Q1 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2022 | first_quarter | PHA | Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program, including the Closing Loopholes for Orphan Drugs Act (H.R. 853). | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-08T11:48:12-04:00 | |
| 2770797 | HOLLAND & KNIGHT LLP 5b340f3b-f305-4058-a230-3935b9bbb00f | Q1 | HOLLAND & KNIGHT LLP | 18466 | VIATRIS INC | 2022 | first_quarter | PHA | Drug shortages, formulary tiering, Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021 (H.R. 2846), biosimilar uptake, Medicare generics penalty, generic drugs issues, supply chain issues, e-labeling provision in the FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill (H.R. 4356), and Military Construction, Veterans Affairs, and Related Agencies appropriations bill (H.R. 4355), Prescription Drug Pricing Dashboard Act (S. 1773); drug pricing; Build Back Better Act (H.R. 5376); Enhanced Access to Affordable Medicines Act of 2022 (H.R. 6973); Increasing Transparency in Generic Drug Applications Act of 2022 (H.R. 7032); Generic Drug User Fee Amendments. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-08T16:18:13-04:00 | |
| 2771076 | CONNECT 4 STRATEGIES, LLC 0bc01ccf-fba0-4ee3-a189-ae22caf51910 | Q1 | CONNECT 4 STRATEGIES, LLC | 401103720 | OREXO US, INC. | 2022 | first_quarter | PHA | Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-09T19:26:20-04:00 | |
| 2771382 | POLSINELLI PC 28625e2a-6981-4879-b165-6f97e5aae5f8 | Q1 | POLSINELLI PC | 314911 | TEVA PHARMACEUTICALS USA, INC. | 2022 | first_quarter | PHA | Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2022-04-11T11:46:38-04:00 | |
| 2771645 | PANNONE LOPES DEVEREAUX & O'GARA LLC db06a7fe-52ba-4d34-a7d6-f3504f18a059 | Q1 | PANNONE LOPES DEVEREAUX & O'GARA LLC | 401105501 | AMGEN | 2022 | first_quarter | PHA | Prescription drug pricing. | 9000 | 0 | 0 | 2022-04-11T16:40:13-04:00 | ||
| 2771815 | AMERICAN PHARMACISTS ASSOCIATION 4dd1cff4-6dff-480d-b120-0beed0556848 | Q1 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2022 | first_quarter | PHA | H.R. 3554/S.1909 The Pharmacy DIR Reform To Reduce Senior Drug Costs Act, to amend title XVIII of the Social Security Act to reform requirements with respect to direct and indirect remuneration under Medicare part D, and for other purposes. H.R. 3662 -- The Patient Access to Urgent-Use Pharmacy Compounding Act of 2021, to amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain urgent-use compounded medications, and for other purposes. H.R. 3682 --To amend title XI of the Social Security Act to provide greater transparency for discounts provided by manufacturers. H.R. 2608 --Ensuring Seniors Access to Local Pharmacies Act of 2021, a bill that establishes several requirements for prescription drug plans under the Medicare prescription drug benefit. H.R. 7213 - To amend title XVIII of the Social Security Act to provide pharmacy reimbursement for COVID-19-related and future emergency services. | HOUSE OF REPRESENTATIVES,SENATE | 35000 | 0 | 0 | 2022-04-12T09:34:20-04:00 | |
| 2771879 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING d575133d-a719-48db-8316-d331f0bc254f | Q1 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 35968 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2022 | first_quarter | PHA | Compounding, preparation, packaging and dispensing of radiopharmaceuticals | Food & Drug Administration (FDA) | 60000 | 0 | 0 | 2022-04-12T10:29:48-04:00 | |
| 2772208 | ACADEMY OF MANAGED CARE PHARMACY 4b18f3f2-177b-472f-b178-6d867ef08e69 | Q1 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2022 | first_quarter | PHA | Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs. Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D. S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products | HOUSE OF REPRESENTATIVES,SENATE | 110000 | 0 | 0 | 2022-04-12T14:08:43-04:00 | |
| 2772492 | INDEPENDENT PHARMACY COOPERATIVE dc17e493-9cbf-4fbc-9871-e7271c204832 | Q1 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2022 | first_quarter | PHA | IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs(CMS-4192-P). Support with amendments. IPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies IPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion. IPC supports MCO Medicaid reform and elimination of spread pricing | Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 30000 | 0 | 0 | 2022-04-12T17:55:26-04:00 | |
| 2772528 | LUNGREN LOPINA LLC f458006b-0317-4cbf-bb02-2361dedbfcd8 | Q1 | LUNGREN LOPINA LLC | 401103314 | AMPAC FINE CHEMICALS | 2022 | first_quarter | PHA | Fair treatment for US based pharmaceutical ingredients | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2022-04-12T20:19:59-04:00 | |
| 2772609 | PUBLIC CITIZEN ff9af9af-b94d-4724-b3bd-dd9224963597 | Q1 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2022 | first_quarter | PHA | HR 5376-Build Back Better Act-drug pricing measures, pandemic preparedness and vaccine manufacturing, HR 6000 (CURES 2.0) antimicrobial development provisions, HR 4502-FY22 Consolidated Appropriations Act-Covid-19 vaccine manufacturing, Affordable Insulin NOW Act, Discounted drugs for clinical trials act, Pharmaceutical Research and transparency, S 2891-Restoring the America Invents Act, HR 4521-America COMPETES act, Plain prescription Prices act, S 3799-PREVENT Pandemics Act, COVID 19 vaccine manufacturing and delivery. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2022-04-13T09:38:09-04:00 | |
| 2773031 | KOUNTOUPES DENHAM CARR & REID, LLC 0dcdcb6e-2524-49dd-acc9-6c7c33fa141b | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | GLENMARK PHARMACEUTICALS, INC., USA | 2022 | first_quarter | PHA | Issues related to affordability, essential medicine manufacturing and pharmaceuticals. General issues related to the generic drug industry. Issues related to H.R. 2853, the BLOCKING Act of 2021. Issues related to pharmaceutical provisions in H.R. 5376, the Build Back Better Act. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-13T15:08:40-04:00 | |
| 2773640 | TARPLIN, DOWNS & YOUNG, LLC 1e1e4a1c-8809-49f1-9b2b-575817efe799 | Q1 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | ASTRAZENECA | 2022 | first_quarter | PHA | Drug coverage & reimbursement vaccination user fees no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2022-04-14T10:53:06-04:00 | |
| 2773840 | TARPLIN, DOWNS & YOUNG, LLC 7fec83a6-fea7-4934-bd50-d8ef32b3f38a | Q1 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | BIOTECHNOLOGY INDUSTRY ORGANIZATION | 2022 | first_quarter | PHA | no specific bills, drug safety, prescription drug importation, import safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, innovation, transparency | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2022-04-14T12:20:39-04:00 | |
| 2773939 | TARPLIN, DOWNS & YOUNG, LLC 7a4fda1e-0570-4a08-a859-123b7d665011 | Q1 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) | 2022 | first_quarter | PHA | ppioid abuse - general issues related to opioid abuse; issues related to ARCOS data and suspicious order record requirements and reporting (HR 768), user fee reauthorization Importation of Prescription Drugs (HR 832, HR 2181, S 259, S 920, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2022-04-14T13:04:04-04:00 | |
| 2774321 | DESIMONE CONSULTING, LLC 71457dcb-fe26-4237-b565-339c3ba748c5 | Q1 | DESIMONE CONSULTING, LLC | 400931695 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2022 | first_quarter | PHA | Issues related to patient access and pricing; Issues related to policy changes to Medicare Part D; PDUFA Reauthorization; FY2022 Budget Reconciliation (H.R.5376). | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2022-04-14T15:20:46-04:00 | |
| 2774635 | GOVERNMENT COUNSEL, LLC 6ee397d6-314f-49dc-a7f8-213680a80bb4 | Q1 | GOVERNMENT COUNSEL, LLC | 401105070 | HEALTHCARE DISTRIBUTION ALLIANCE | 2022 | first_quarter | PHA | Implementation of Public Law 113-54 (DSCSA). | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-14T18:17:15-04:00 | |
| 2774642 | DAVE KOLBE CONSULTING 138ac413-eb25-4546-ada9-707582779e3f | Q1 | DAVE KOLBE CONSULTING | 401104329 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2022 | first_quarter | PHA | Reauthorization of the Prescription Drug User Fee Act (PDUFA) - Support for a strong PDUFA reauthorization that ensures Americans will continue to have first access to life-saving biopharmaceutical medicines throughout the length of the reauthorization. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2022-04-14T18:50:31-04:00 | |
| 2774683 | FOLEY & LARDNER LLP 60dd0078-572b-4f9b-9bc1-91002a25db80 | Q1 | FOLEY & LARDNER LLP | 15042 | BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) | 2022 | first_quarter | PHA | Market-based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-14T23:08:34-04:00 | |
| 2774808 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER fcee4152-0716-4b1a-bb86-796730c86dfd | Q1 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2022 | first_quarter | PHA | 340B, white bagging, PDUFA | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 34560 | 0 | 0 | 2022-04-15T09:18:52-04:00 | |
| 2775263 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 3e55dc4f-89e9-4e3b-bdc1-943ffd7c4a5d | Q1 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2022 | first_quarter | PHA | S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; Draft legislation, Prescription Information Modernization Act; | Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 2010000 | 0 | 0 | 2022-04-15T12:47:27-04:00 | |
| 2775577 | NELSON MULLINS RILEY & SCARBOROUGH b4ca2e8f-04ab-456f-b255-392954bbf08a | Q1 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | HEMOPHILIA OF GEORGIA | 2022 | first_quarter | PHA | 340B Drug Pricing Program, Medicare, patient co-pay policies | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2022-04-15T14:37:06-04:00 | |
| 2775781 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 0b6b8537-f9af-49ed-8509-289181a22a30 | Q1 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 401104060 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 2022 | first_quarter | PHA | General education around pharmaceuticals related to Parkinson's disease Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, and streamlining prior authorization processes and step therapy protocols Prescription Drug User Fee Act H.R. 4417, the Capping Drug Costs for Seniors Act H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics Act of 2021 S. 2327, the Seniors Prescription Drug Relief Act H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021 H.R. 2163, the Safe Step Act H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 57949 | 0 | 0 | 2022-04-15T16:19:13-04:00 | |
| 2776101 | FORBES-TATE aa9540ac-048f-419f-b039-3ab692de7d8f | Q1 | FORBES-TATE | 400976792 | CALIFORNIA LIFE SCIENCES ASSOCIATION | 2022 | first_quarter | PHA | Issues related to the life sciences industry; Issues related to drug pricing and international reference pricing. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2022-04-15T20:01:24-04:00 | |
| 2776372 | FORBES-TATE cadff849-3f47-4953-8061-8eda7d398998 | Q1 | FORBES-TATE | 400976792 | INDEPENDENT PHARMACY COOPERATIVE | 2022 | first_quarter | PHA | Issues related to pharmacy regulation, the MAC Transparency Act, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-16T10:54:37-04:00 | |
| 2776564 | FOLEY & LARDNER LLP 46f4bd04-d94e-401f-bdb7-1dd4d8b693f1 | Q1 | FOLEY & LARDNER LLP | 15042 | ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 2022 | first_quarter | PHA | FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2022-04-16T14:44:29-04:00 | |
| 2776628 | CAPITOL COUNSEL LLC 7a01cb6c-473d-4283-9906-89f4108d14fa | Q1 | CAPITOL COUNSEL LLC | 313715 | EMD SERONO, INC. | 2022 | first_quarter | PHA | Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-16T16:01:12-04:00 | |
| 2776676 | CAPITOL COUNSEL LLC b7e93d32-f8f0-41b9-991e-d44d1b688af2 | Q1 | CAPITOL COUNSEL LLC | 313715 | VERTEX PHARMACEUTICALS INCORPORATED | 2022 | first_quarter | PHA | Monitoring and advocacy on matters related to the pharmaceutical industry. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-16T16:31:13-04:00 | |
| 2776778 | BROYDRICK & ASSOCIATES cb38fd34-dabf-4553-8344-2956ea360ffd | Q1 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2022 | first_quarter | PHA | Funding new drug for PTSD and COVID 19. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2022-04-16T17:50:53-04:00 | |
| 2776813 | FOLEY & LARDNER LLP f9ee39d2-c7fd-44b8-a064-b6e1fb0ca34f | Q1 | FOLEY & LARDNER LLP | 15042 | FOUNDATION CONSUMER HEALTHCARE LLC | 2022 | first_quarter | PHA | Legislation and regulations affecting marketing and commercialization of prescription and non-prescription drugs | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2022-04-16T19:17:24-04:00 | ||
| 2777103 | FORBES-TATE c3dd45b6-afcd-4ac3-92bb-18c7832622ca | Q1 | FORBES-TATE | 400976792 | PHRMA | 2022 | first_quarter | PHA | Issues pertaining to prescription drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2022-04-17T12:10:09-04:00 | |
| 2777111 | BOCKORNY GROUP, INC. 674e787b-45ab-4219-b7e5-645bc3bc1768 | Q1 | BOCKORNY GROUP, INC. | 289773 | CVS HEALTH INC | 2022 | first_quarter | PHA | Issues related to PBMs Issues related to drug pricing Issues related to health reform proposals Issues related to representation in COVID-19-related packages HR 1319 American Rescue Plan | Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 60000 | 0 | 0 | 2022-04-17T12:12:58-04:00 | |
| 2777231 | RED+BLUE STRATEGIES 6fe6e9bd-4f64-4f7b-b501-ce4373fe95aa | Q1 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2022 | first_quarter | PHA | H.R. 2571 Consolidated Appropriations Act for Fiscal Year 2022 - Issues related to the use of rebates and other cost savings tools used by pharmacy benefit managers Issues and legislative vehicles related to capping the price of Insulin. Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR). H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule. PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2022-04-17T14:49:04-04:00 | |
| 2777307 | ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) 9abb46fc-2034-4421-a594-264255f3bef1 | Q1 | ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) | 400762305 | AMERISOURCEBERGEN CORPORATION | 2022 | first_quarter | PHA | Issues related to drug pricing and transparency, generally. Issues related to the importation of prescription medicines Issues related to the pharmaceutical supply chain and stockpiling Issues related to COVID vaccine distribution | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2022-04-17T16:02:31-04:00 | |
| 2777343 | ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) 743981bc-a9be-4270-8b88-799ec2d4a3a3 | Q1 | ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) | 400762305 | PHRMA (PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA) | 2022 | first_quarter | PHA | Issues relating to drug pricing, value and transparency, generally. Issues relating to medical research and development, as well as access to medicines | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2022-04-17T16:20:58-04:00 | ||
| 2777483 | FORBES-TATE 10a970a3-31ad-4d54-8c81-5e9892faab19 | 1T | FORBES-TATE | 400976792 | VERDE TECHNOLOGIES | 2022 | first_quarter | PHA | Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2022-04-17T19:21:08-04:00 | ||
| 2777598 | CORNERSTONE GOVERNMENT AFFAIRS, INC. 9bd7417b-a541-4c94-a2f1-f905ac53e70c | Q1 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | CHILDREN'S NATIONAL MEDICAL CENTER | 2022 | first_quarter | PHA | Representation on health-related issues including reimbursement, research, public-health & clinical care | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2022-04-17T21:49:00-04:00 | |
| 2777686 | MARSHALL & POPP, LLC 6b071f1c-f9ea-4637-aa9a-b314d51e7279 | Q1 | MARSHALL & POPP, LLC | 401105121 | AMGEN USA INC. | 2022 | first_quarter | PHA | Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B and ESRD. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-18T06:41:42-04:00 | |
| 2777692 | MARSHALL & POPP, LLC b654b8fe-adde-444d-a230-bb32d6579364 | Q1 | MARSHALL & POPP, LLC | 401105121 | BUTTERFLY NETWORK, INC. | 2022 | first_quarter | PHA | Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-18T06:45:44-04:00 | |
| 2778131 | FAEGRE DRINKER BIDDLE & REATH LLP 0bb3ed15-6294-4f96-98a7-24877d3cdc6d | Q1 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | NATIONAL ASSOCIATION OF BOARDS OF PHARMACY | 2022 | first_quarter | PHA | Medication safety, pharmacy regulation and licensure, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R.2482, S. 2074 - Mainstreaming Addiction Treatment Act; Prescription drug importation; H.R. 6352, S. 3399 - Domain Reform for Unlawful Drug Sellers Act. | Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2022-04-18T11:00:11-04:00 | |
| 2778244 | AMERICAN VETERINARY MEDICAL ASSOCIATION cee6f881-d049-47e3-8751-7bf94a5ac7c8 | Q1 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2022 | first_quarter | PHA | -Review of Food and Drug Administrations Draft guidance #256 for industry: Compounding Animal Drugs from Bulk Drug Substance Prescription Mandate legislation Animal Drug User Fee Act/ Animal Generic Drug User Fee Act reauthorization | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 320000 | 0 | 0 | 2022-04-18T11:19:34-04:00 | |
| 2778427 | LINCOLN PARK GROUP L.L.C. aec8b081-ae4a-4331-84d0-c75dfef2b0b7 | Q1 | LINCOLN PARK GROUP L.L.C. | 401104374 | CANADIAN INTERNATIONAL PHARMACY ASSOCIATION | 2022 | first_quarter | PHA | Support for S. 920/H.R. 2181 - A bill to amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals and S. 259/H.R. 832 - Safe and Affordable Drugs from Canada Act; S. 3399/H.R. 6532 Domain Reform for Unlawful Drug Sellers Act; S. 3984, Stop Illegal Online Sales of Controlled Substances Act; and other issues related to personal drug importation. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2022-04-18T11:51:47-04:00 | |
| 2778512 | UNIVERSITY OF IOWA f317819a-7343-4d29-b261-db5cf36abf1f | Q1 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2022 | first_quarter | PHA | N/A | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-18T12:08:43-04:00 | |
| 2778595 | MLJ STRATEGIES bf98d0ef-2a21-43d4-96a7-11b4de5ee050 | Q1 | MLJ STRATEGIES | 401105126 | ANKURA CONSULTING GROUP, LLC ON BEHALF OF ON DEMAND PHARMACEUTICALS | 2022 | first_quarter | PHA | Advocating on issues related to pharmaceutical appropriations | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2022-04-18T12:23:23-04:00 | ||
| 2778642 | MLJ STRATEGIES 3827784a-80a0-4154-ae02-af6aa33a5418 | Q1 | MLJ STRATEGIES | 401105126 | ANKURA CONSULTING GROUP, LLC ON BEHALF OF THORNE RESEARCH | 2022 | first_quarter | PHA | Advocate on issues related to supplement use in the military | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2022-04-18T12:27:25-04:00 | ||
| 2778878 | KOUNTOUPES DENHAM CARR & REID, LLC 6cbb8f34-dc48-4a9c-a389-7a2ecef3c7e0 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) | 2022 | first_quarter | PHA | Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing measures in H.R. 5376, the Build Back Better Act. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA). | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-18T13:00:56-04:00 | |
| 2778998 | K&L GATES, LLP db0037ff-3349-46e3-857e-5746080e54b4 | Q1 | K&L GATES, LLP | 32098 | PRN SOFTWARE | 2022 | first_quarter | PHA | Issues related to COVID-19 antiviral deployment - no specific legislation. | White House Office | 30000 | 0 | 0 | 2022-04-18T13:19:36-04:00 | |
| 2779164 | KOUNTOUPES DENHAM CARR & REID, LLC 85360a73-9b93-47a8-8bff-5b4bbfcedaf2 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) | 2022 | first_quarter | PHA | Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to pharmacy provider status. Issues related to pharmaceutical supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to drug pricing in H.R. 5376, the Build Back Better Act. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-18T13:50:13-04:00 | |
| 2779654 | BLUECROSS BLUESHIELD OF TENNESSEE ec0918d8-0512-4dde-9e88-d6b747d45ba2 | Q1 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2022 | first_quarter | PHA | COVID-19 Testing; Vaccine Strategy and Treatment; Prescription Drug Reform Educated Congressional Members on our Specialty Pharmacy Program and Savings We've Seen Thus Far H.R. 3 - Lower Drug Costs Now Act Sponsor: Rep. Frank Pallone | HOUSE OF REPRESENTATIVES,SENATE | 330000 | 0 | 0 | 2022-04-18T15:06:40-04:00 | |
| 2779798 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 9dcf2407-b08d-47a2-bf2e-88e61cf0a1c4 | Q1 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2022 | first_quarter | PHA | Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies. | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 355000 | 0 | 0 | 2022-04-18T15:26:49-04:00 | |
| 2779939 | THERMO FISHER SCIENTIFIC INC. 8c12cc10-dc39-4dd5-b08f-ae99a457b97b | Q1 | THERMO FISHER SCIENTIFIC INC. | 323251 | THERMO FISHER SCIENTIFIC INC | 2022 | first_quarter | PHA | Worker training program (H.R. 5993). | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 740000 | 0 | 0 | 2022-04-18T15:58:31-04:00 | |
| 2780576 | MCDERMOTT+ LLC 2b8f61a1-9b5e-4211-8178-36e823d10197 | Q1 | MCDERMOTT+ LLC | 401103287 | CAMPAIGN FOR SUSTAINABLE DRUG PRICING | 2022 | first_quarter | PHA | S. 1391 - Fair Accountability and Innovative Research Drug Pricing Act. Prescription drug pricing issues. Patent abuse issues. Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021. Drug-price Transparency for Competition (DTC) Act. H.R. 5376 - Build Back Better Act. Prescription Drug User Fee Act. H.R. 6833 - Affordable Insulin Now Act. National Coverage Determination on Aduhelm. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 30000 | 0 | 0 | 2022-04-18T17:44:00-04:00 | |
| 2780799 | PORT SIDE STRATEGIES, LLC 26cd25ed-820a-424f-bec3-7e47d60f42d0 | Q1 | PORT SIDE STRATEGIES, LLC | 401105394 | NEW VENTURE FUND | 2022 | first_quarter | PHA | Lobbied in support of including drug pricing reforms in the reconciliation bill. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2022-04-18T19:33:25-04:00 | ||
| 2780892 | BLUESTONE STRATEGIES, LLC cbebd08f-2229-43fd-8a06-877bd1ab86e0 | Q1 | BLUESTONE STRATEGIES, LLC | 400658980 | AMERICA'S HEALTH INSURANCE PLANS (AHIP) | 2022 | first_quarter | PHA | HR 3, Lower Drug Costs Now Act; HR 5260, Reduced Cost and Continued Care Act; Specialty Drugs and Prescription Drug Pricing, HR 19. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-18T20:17:22-04:00 | |
| 2780932 | BLUESTONE STRATEGIES, LLC dce39f4c-fc9c-45f4-bd1a-113e012aabb4 | Q1 | BLUESTONE STRATEGIES, LLC | 400658980 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2022 | first_quarter | PHA | Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-18T20:34:16-04:00 | |
| 2780972 | MARSHALL & POPP, LLC 01be289e-900d-45fd-a147-f82633135703 | Q1 | MARSHALL & POPP, LLC | 401105121 | GENENTECH, INC. | 2022 | first_quarter | PHA | Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-18T21:02:29-04:00 | |
| 2781004 | MARSHALL & POPP, LLC ef103652-5673-44f0-98d2-ab2edb1f1f30 | Q1 | MARSHALL & POPP, LLC | 401105121 | PFIZER, INC. | 2022 | first_quarter | PHA | Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-18T21:17:58-04:00 | |
| 2781009 | MARSHALL & POPP, LLC 9b3430ba-a93c-431d-bbf5-ac94c096b895 | Q1 | MARSHALL & POPP, LLC | 401105121 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2022 | first_quarter | PHA | Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res.14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2022-04-18T21:21:43-04:00 | |
| 2781013 | MARSHALL & POPP, LLC 82669abc-733c-4674-9a77-ac3939d3c21c | Q1 | MARSHALL & POPP, LLC | 401105121 | SANOFI U.S. SERVICES, INC. | 2022 | first_quarter | PHA | Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res.14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-18T21:24:17-04:00 | |
| 2781514 | TRAVERE THERAPEUTICS 53431626-f2f2-4ea2-8a4f-41d262a5b989 | Q1 | TRAVERE THERAPEUTICS | 401104190 | TRAVERE THERAPEUTICS | 2022 | first_quarter | PHA | H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act. Legislative proposals regarding drug pricing, value, and reimbursement in H.R. 5736 Build Back Better Act and related Senate legislation. | HOUSE OF REPRESENTATIVES,SENATE | 210000 | 0 | 0 | 2022-04-19T08:43:25-04:00 | |
| 2781684 | VAN SCOYOC ASSOCIATES fdca8dfd-66c1-44f5-badf-08be552a42c7 | Q1 | VAN SCOYOC ASSOCIATES | 39837 | ZEBRA TECHNOLOGIES CORP. | 2022 | first_quarter | PHA | Temperature monitoring technology for COVID vaccines, Domestic and International distribution related issues Temperature monitoring technology, COVID Rapid Diagnostic Test Kits S.3799, PREVENT Pandemics Act, Rapid Diagnostic Test related issues | HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2022-04-19T09:11:40-04:00 | |
| 2781880 | CONCERNED WOMEN FOR AMERICA LEGISLATIVE ACTION COMMITTEE e9bfd651-dd91-4417-81c6-905301d534e1 | Q1 | CONCERNED WOMEN FOR AMERICA LEGISLATIVE ACTION COMMITTEE | 47985 | CONCERNED WOMEN FOR AMERICA LEGISLATIVE ACTION COMMITTEE | 2022 | first_quarter | PHA | Lobbied Senate against Dr. Robert Califf's nomination to be Commissioner of the Food and Drug Administration due to his weakening of the REMS for the chemical abortion pill | SENATE | 9000 | 0 | 0 | 2022-04-19T09:28:51-04:00 | |
| 2781986 | MEHLMAN CONSULTING, INC. 09b0f0d2-4d8c-4dd2-a709-a87722be8a80 | 1T | MEHLMAN CONSULTING, INC. | 284950 | AMNEAL | 2022 | first_quarter | PHA | Monitoring legislative and regulatory efforts related to domestic supply chains of generic drugs. Pandemic Preparedness. H.R. 5376 - Build Back Better Act. S. 3799 - PREVENT Pandemics Act. | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 40000 | 0 | 1 | 2022-04-19T09:38:06-04:00 | |
| 2782359 | BUCHANAN INGERSOLL & ROONEY PC 534a9804-d614-489b-8075-ab627d5e09a8 | Q1 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | FERA PHARMACEUTICALS, LLC | 2022 | first_quarter | PHA | Strategy development and implementation of federal government relations initiatives relating to phospholine iodide issues with the Food and Drug Administration and Centers for Medicare and Medicaid Services. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2022-04-19T10:11:05-04:00 | |
| 2782426 | BUCHANAN INGERSOLL & ROONEY PC c61ee09f-0b9e-48f8-bb98-1f744938de54 | Q1 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | GENERIC ANIMAL DRUG ALLIANCE | 2022 | first_quarter | PHA | Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2022-04-19T10:15:06-04:00 | |
| 2782561 | KOUNTOUPES DENHAM CARR & REID, LLC 095393aa-cec4-4770-a19e-69124cf01d5c | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2022 | first_quarter | PHA | General issues related to over-the-counter pharmaceutical supply chain. Issues related to dietary supplements. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-19T10:28:39-04:00 | |
| 2782611 | WATKINS & EAGER PLLC 950235cc-780a-4d25-9b25-a1c453b32d73 | Q1 | WATKINS & EAGER PLLC | 401104403 | ZYNERBA PHARMACEUTICALS, INC. | 2022 | first_quarter | PHA | Providing services on behalf of Zynerba to the pharmaceutical industry - looking for testing sites | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2022-04-19T10:31:47-04:00 | |
| 2782723 | ELI LILLY AND COMPANY 1df8b4fa-530c-4fe6-82e3-612eeb8bee0b | Q1 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2022 | first_quarter | PHA | Hospital discounts; 340B program; Affordable Prescriptions for Patients Act of 2021 (S.1435) | HOUSE OF REPRESENTATIVES,SENATE | 1510000 | 0 | 0 | 2022-04-19T10:40:56-04:00 | |
| 2782855 | BLUE CROSS AND BLUE SHIELD ASSOCIATION 0da5d816-b539-4582-b704-ca8bdba93454 | Q1 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 6358 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 2022 | first_quarter | PHA | COVID-19 Testing; Rx reform; Prescription drugs; Prescription Drug Reform; OTC COVID Tests; Insulin; H.R. 3 - Lower Drug Costs Now Act Sponsor: Rep. Frank Pallone (D-NJ-06) | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 1450000 | 0 | 0 | 2022-04-19T10:51:22-04:00 | |
| 2782887 | VENTURE GOVERNMENT STRATEGIES, LLC (FKA HOBART HALLAWAY & QUAYLE VENTURES, LLC) 5003d998-f245-45aa-be80-c7d9575edbd2 | Q1 | VENTURE GOVERNMENT STRATEGIES, LLC (FKA HOBART HALLAWAY & QUAYLE VENTURES, LLC) | 401103475 | RX SAVINGS, LLC DBA RX SAVINGS SOLUTIONS | 2022 | first_quarter | PHA | Issues related to healthcare consumerism and pharmacy transparency. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2022-04-19T10:53:48-04:00 | |
| 2783251 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 8dda1318-ed85-4e9e-a565-cffd5cd8df22 | Q1 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2022 | first_quarter | PHA | OTC switch process -- no bill number Cures 2.0 -- no bill number S.1435/HR 2873 - Affordable Prescriptions for Patients Act of 2021 H.R.4405 - Small Business FDA User Fee Adjustment Act of 2021 Prescription Drug User Fee Act (PDUFA) -- no bill number Dietary Supplement Reform -- no bill number Cosmetics Reform -- no bill number | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 156000 | 0 | 0 | 2022-04-19T11:17:31-04:00 | |
| 2783285 | BOLD STRATEGIES, LLC 00c4d738-849d-4fdd-a337-0b3f7cc9afe7 | Q1 | BOLD STRATEGIES, LLC | 401104653 | MORRIS & DICKSON CO., LLC | 2022 | first_quarter | PHA | Prescription drug issues generally. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2022-04-19T11:20:00-04:00 | |
| 2783577 | TWENTY-FIRST CENTURY GROUP, INC. 83a28a2d-735c-4784-91d7-e1931a568dac | Q1 | TWENTY-FIRST CENTURY GROUP, INC. | 38687 | CARDINAL HEALTH, INC. | 2022 | first_quarter | PHA | Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response; and the healthcare supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2022-04-19T11:43:32-04:00 | |
| 2783655 | WAXMAN STRATEGIES eaac0a21-7886-4208-9716-f66efe3311a0 | Q1 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2022 | first_quarter | PHA | Issues affecting the 340B drug pricing program; Appropriations for 340B program. | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2022-04-19T11:51:12-04:00 | |
| 2784512 | RED+BLUE STRATEGIES 7a536919-5a25-4dfe-8ec8-a8ef54f113db | Q1 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2022 | first_quarter | PHA | S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. H.R. 5376 - Build Back Better Act - Continued advocacy for issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-19T13:04:58-04:00 | |
| 2784590 | E3 STRATEGIC CONSULTING GROUP 8e0ac182-3a0a-452a-9fdc-4ba2f62d7f53 | Q1 | E3 STRATEGIC CONSULTING GROUP | 401104104 | HEINZ STRATEGIES LLC (ON BEHALF OF PILMA) | 2022 | first_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally; | HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2022-04-19T13:11:52-04:00 | |
| 2784600 | E3 STRATEGIC CONSULTING GROUP 7b10b6cb-265d-4a64-aa69-cb8f003d8e0d | Q1 | E3 STRATEGIC CONSULTING GROUP | 401104104 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2022 | first_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally; | HOUSE OF REPRESENTATIVES | 20000 | 0 | 0 | 2022-04-19T13:12:43-04:00 | |
| 2784896 | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 1e265db3-2322-4f52-99a9-57cb2828c52d | Q1 | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. | 6382 | BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 2022 | first_quarter | PHA | COVID-19 Testing; Rx Reform; Prescription Drugs; Prescription Drug Reform; OTC COVID-19 Tests; Insulin HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 240000 | 0 | 0 | 2022-04-19T13:42:29-04:00 | |
| 2784965 | GUIDEWELL MUTUAL HOLDING CORPORATION 729e6c4f-8b47-4b5e-9fad-31ed7b6331a2 | Q1 | GUIDEWELL MUTUAL HOLDING CORPORATION | 401103191 | GUIDEWELL MUTUAL HOLDING CORPORATION | 2022 | first_quarter | PHA | COVID-19 Testing; Rx Reform; Prescription Drugs; Prescription Drug Reform; OTC COVID-19 Tests; Insulin HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 0 | 0 | 2022-04-19T13:48:08-04:00 | ||
| 2785572 | KOUNTOUPES DENHAM CARR & REID, LLC 7b010a5f-493d-4ed6-9cfe-89fb6439661a | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2022 | first_quarter | PHA | General education about the pharmacy benefit manager/pharmacy and insurance industry. Issues related to drug pricing. Issues related to the drug supply chain. Issues related to the implementation of H.R. 1319, The American Rescue Plan, including provisions related to vaccine distribution. Issues related to the Fiscal Year 2022 budget reconciliation process focusing on drug pricing, including H.R. 5376, the Build Back Better Act. Issues related to pharmacy provider status. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2022-04-19T14:44:07-04:00 | |
| 2785772 | REPUBLIC CONSULTING, LLC 34b30993-6f86-4b91-95d8-637155c38d10 | Q1 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2022 | first_quarter | PHA | Monitored Health Data Policy. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE | 60000 | 0 | 0 | 2022-04-19T14:58:31-04:00 | |
| 2786295 | BROWN & FORTUNATO, P.C. 25a3e987-8fdb-4a7f-b437-02c09f021191 | Q1 | BROWN & FORTUNATO, P.C. | 401104878 | PROMPTCARE COMPANIES, INC. | 2022 | first_quarter | PHA | Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators. | Centers For Medicare and Medicaid Services (CMS) | 20000 | 0 | 0 | 2022-04-19T15:30:39-04:00 | |
| 2786868 | AKIN GUMP STRAUSS HAUER & FELD 406bdc94-acc9-4bdb-927d-d37a56a4a409 | Q1 | AKIN GUMP STRAUSS HAUER & FELD | 682 | UNITED STATES PHARMACOPEIAL CONVENTION | 2022 | first_quarter | PHA | Compounding; Drug Pricing; 21st Century Cures Act 2.0; COVID-19 pandemic response; Supply chain reform; American Rescue Plan Act (P.L. 117-2); FY 2022 Appropriations; Cannabis; Infrastructure and budget reconciliation legislation. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2022-04-19T16:13:53-04:00 | |
| 2787007 | AARP e6e53049-e7f7-4ac3-80cc-06cdd8e43bb6 | Q1 | AARP | 1694 | AARP | 2022 | first_quarter | PHA | No bill number. Discussed prescription drug legislation and policies to lower prescription drug prices. H.R.5376, the Build Back Better Act. S.3700/H.R.6833, the Affordable Insulin Now Act. No bill number. Discussed disclosure of prescription drug prices in television ads. No bill number. Discussed inappropriate use of antipsychotic drugs in nursing homes. H.R. 4356, the FY 2022 Agriculture, Rural Development & FDA Appropriations. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 3530000 | 0 | 0 | 2022-04-19T16:23:06-04:00 | |
| 2787071 | HANCE SCARBOROUGH 93147ef9-df5f-4a80-9368-31fe4c532eba | Q1 | HANCE SCARBOROUGH | 17443 | ALLIANCE FOR PHARMACY COMPOUNDING | 2022 | first_quarter | PHA | Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2022 Appropriations HR3662, the Patient Access to Urgent Use Compounded Medication Act | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2022-04-19T16:27:00-04:00 | |
| 2787240 | HANCE SCARBOROUGH 990bfc96-a9ac-4646-b377-7e8d2e0e7a32 | Q1 | HANCE SCARBOROUGH | 17443 | PHRMA | 2022 | first_quarter | PHA | Patent reform regarding pharmaceutical research & products. | SENATE | 30000 | 0 | 0 | 2022-04-19T16:38:35-04:00 | |
| 2787298 | RAMPY NORTHRUP LLC 00f2f6a6-08c9-49ff-9bb2-1db451516e52 | Q1 | RAMPY NORTHRUP LLC | 401103289 | ASTRAZENECA PHARMACEUTICALS LP | 2022 | first_quarter | PHA | Provide legislative and regulatory advice related to vaccine development, drug pricing, the 340B Drug Pricing Program, PDUFA Reauthorization, and clinical trial diversity; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation (H.R.5376); H.R.5585, Advanced Research Project Agency-Health Act; H.R.5030/S.2706, DIVERSE Trials Act. | HOUSE OF REPRESENTATIVES | 60000 | 0 | 0 | 2022-04-19T16:40:55-04:00 | |
| 2787600 | RICCHETTI INCORPORATED 56470a95-b06d-4abb-86ac-7e3439581022 | Q1 | RICCHETTI INCORPORATED | 62778 | EISAI, INC. | 2022 | first_quarter | PHA | Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2022-04-19T17:01:24-04:00 | |
| 2787628 | SQUIRE PATTON BOGGS 2e84b74b-a974-4c84-8f19-cae468525995 | Q1 | SQUIRE PATTON BOGGS | 30906 | SK HYNIX AMERICA, INC. | 2022 | first_quarter | PHA | Monitor proposals and issues related to biopharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2022-04-19T17:04:14-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);